Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects

Bays, Harold, Pi-Sunyer, Xavier, Hemmingsson, Joanna Uddén, Claudius, Birgitte, Jensen, Christine B., Van Gaal, Luc · 2017 · Current Medical Research and Opinion

Abstract

OBJECTIVE: As an adjunct to a reduced-calorie diet and increased physical activity, treatment with liraglutide 3.0 mg for weight management provides a statistically significant and clinically meaningful weight loss of 5.7%-8.0% compared to 1.6%-2.6% with placebo. The objective of this post hoc analysis was to quantify the relative contribution of weight loss to the treatment effects of liraglutide 3.0 mg on key efficacy endpoints. METHODS: The analysis utilized data from 4725 participants across three randomized, placebo-controlled, double-blind trials that evaluated the efficacy and safety of liraglutide 3.0 mg versus placebo, as an adjunct to a reduced-calorie diet and increased physical activity (ClinicalTrials.gov identifiers: NCT01272219, NCT01272232 and NCT01557166). The duration of two of the trials was 56 weeks; one trial was of 32 weeks' duration. A mediation analysis was performed, which ranked the relative contribution of weight loss to the treatment effects of liraglutide 3.0 mg on key cardiometabolic efficacy endpoints, Apnea-Hypopnea Index (AHI) and health-related quality of life (QoL). A limitation of this type of analysis is that it cannot conclusively prove a causal relationship. RESULTS: In individuals without type 2 diabetes mellitus (T2DM), endpoints predominantly driven by liraglutide-induced weight loss included waist circumference, diastolic blood pressure, triglycerides, high density lipoprotein cholesterol, AHI, and Impact of Weight on Quality of Life-Lite total and physical function scores. Endpoints predominantly independent of weight loss included the glycemic endpoints hemoglobin A1c and fasting plasma glucose in individuals with and without T2DM. Regardless of the degree of dependence on weight loss according to the mediation analysis, greater weight loss was associated with greater improvement in all endpoints. CONCLUSION: Treatment with liraglutide 3.0 mg contributes to improved cardiometabolic parameters, AHI and health-related QoL through both weight-loss dependent and weight-loss independent mechanisms.

Overview

Integrity signals

Registry

Crossref · 10.1080/03007995.2016.1251892

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 17 references

Research works printed but not linked: 1

  1. American Society for Metabolic and Bariatric Surgery, Obesity Society, American Society of Bariatric Physicians, American Association of Clinical Endocrinologists. Joint press release: obesity is a disease: leading obesity groups agree. PRNewswire website. 2013. Available at: http://www.prnewswire.com/news-releases/obesity-is-a-disease-leading-obesity-groups-agree-212194851.html [Last accessed 15 December 2015]

Cited by

See all 48

Metadata

Authors
Bays, H., Pi-Sunyer, X., Hemmingsson, J. U., Claudius, B., Jensen, C. B., & Van Gaal, L.
Affiliations
  • Louisville Metabolic and Atherosclerosis Research Center (US)
  • Columbia University (US)
  • Capio St Goran’s Hospital/Karolinska Institutet, Stockholm, Sweden;
  • Novo Nordisk (Denmark) (DK)
  • Department of Endocrinology, Diabetology and Metabolism, Faculty of Medicine, Antwerp University Hospital, Edegem, Belgium
Corresponding author
Bays, Harold
Venue
Current Medical Research and Opinion
Published
2016-11-06
Volume
33
Issue
2
Pages
225-229
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W2547039088
Cited by
48
References
17
Citations by year
2026: 4 · 2025: 10 · 2024: 5 · 2023: 6 · 2022: 7 · 2021: 3 · 2020: 1 · 2019: 5 · 2018: 3 · 2017: 3 · 2016: 1
FWCI
3.24
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medical Research and Opinion (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
liraglutide, weight management, weight loss, obesity, type 2 diabetes, cardiometabolic outcomes, apnea-hypopnea index, sleep apnea, health-related quality of life, glycemic control, HbA1c, fasting blood glucose, waist circumference, triglycerides, diastolic blood pressure, GLP-1 receptor agonists, mediation analysis
MeSH terms
Liraglutide, Adult, Aged, Blood Glucose, Blood Pressure, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Quality of Life, Weight Loss, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects. https://app.cochat.ai/papers/10.1080/03007995.2016.1251892
The paper
Bays, H., Pi-Sunyer, X., Hemmingsson, J. U., Claudius, B., Jensen, C. B., & Van Gaal, L. (2017). Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects. Current Medical Research and Opinion. https://doi.org/10.1080/03007995.2016.1251892

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.